Search clinical trials for: interferon gamma 1b

Total 2485 results

Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Interferon Alfa (IFN-Alpha-1b) in Renal Cancer With Metastatic Kidney Cancer

Kidney Cancer

United States
InterMune

Terminated

A Randomized, Double-Blind, Three-Arm, Phase 3b Study Comparing the Safety and Efficacy of Interferon Gamma-1b With Azathioprine, and Azathioprine Alone in Patients With IPF Receiving Prednisone

Pulmonary Fibrosis | Lung Disease

Italy
Transgene

Completed

Study to Evaluate the Safety and Efficacy of Adeno-IFN Gamma in Cutaneous B-cell Lymphoma

Lymphoma, B-Cell

United States, France, Switzerland
SPP Pharmaclon Ltd.

Completed

Efficiency and Safety of the Drug Ingaron (Interferon-gamma Human Recombinant) in the Treatment of Chronic Prostatitis (ING-HP-1)

Chronic Prostatitis
SPP Pharmaclon Ltd.

Completed

Study of the Efficacy and Safety of the Drug Ingaron (Interferon-gamma) in the Treatment of Anogenital Warts (ING-HPV-1)

Human Papillomavirus Infection | Anogenital Warts

Russian Federation
National Cancer Institute (NCI)

Completed

Tumor Vaccine and Interferon Gamma in Treating Patients With Refractory Epithelial Ovarian Cancer

Recurrent Ovarian Epithelial Cancer

United States
SPP Pharmaclon Ltd.

Completed

Study of the Use of the Ingaron in Volunteers for the Prevention of COVID-19

COVID-19 Respiratory Infection

Russian Federation
National Eye Institute (NEI)

Completed

The Treatment of Uveitic Cystoid Macular Edema With Topical Interferon Gamma

Uveitis

United States
Azienda Policlinico Umberto I

Completed

A Phase IIa Trial to Test Safety and Efficacy Interferon Gamma Treatment in Elevating Frataxin Levels in FRDA Patients

Friedreich Ataxia

Italy
University of Rochester
National Cancer Institute (NCI)

Completed

Interferon Gamma in Treating Patients With Recurrent or Metastatic Melanoma or Other Solid Tumors

Unspecified Adult Solid Tumor, Protocol Specific | Melanoma (Skin)

United States
Paola Mantegani

Active, not recruiting

Evaluation of a CD4/CD8+ Interferon Gamma Release Assay for Monitoring Anti-Tuberculosis Treatment (IGRA/MAT-1)

Tuberculosis

Italy
Case Western Reserve University
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Interferon-Gamma Release Assays in Tuberculosis (TB) - HIV Co-infected Children

HIV | Tuberculosis

South Africa
National Institute of Allergy and Infectious Diseases...

Completed

A Randomized, Double-Blinded, Placebo-Controlled, Phase II Inhaled Interferon Gamma-1b and Antimycobacterials to Treat Pulmonary Mycobacterium Avium Complex Infections

Mycobacterium Avium-Intracellulare Infection

United States
Bayer

Completed

Observational Study to Analyse the Impact of Nurse Support and Disease Related Factors on Long- Term Adherence to Betaferon Treatment (BEACON)

Relapsing Remitting Multiple Sclerosis (RRMS)

China, Slovakia, France, Germany, Korea, Republic of, Saudi Arabia, Singapore, Sweden, Taiwan, Colombia, Czech Republic, Estonia, Italy, Jordan, Lebanon, Mexico, Slovenia, United Kingdom, Argentina, Bahrain, Egypt, United Arab Emirates and more
Bayer

Completed

Depression and Fatigue in MS Patients Treated With Betaferon. (FADO)

Multiple Sclerosis

Poland
Bayer

Completed

BENEFIT Extension Study

Multiple Sclerosis

Switzerland, Poland, France, Germany, Hungary, Spain, Sweden, Austria, Czech Republic, Italy, Slovenia, Israel, Belgium, Denmark, Netherlands, Canada, Norway, Finland
Bayer

Completed

Study Evaluating Betaferons Safety and Tolerability In Pediatric Patients With Multiple Sclerosis

Multiple Sclerosis

Germany, Austria, United Kingdom, Israel, Belgium, Finland
Bayer

Completed

BENEFIT Study (Betaferon® / Betaseron® in Newly Emerging Multiple Sclerosis for Initial Treatment) and BENEFIT Follow-up Study

Multiple Sclerosis

Belgium, Italy, Spain, France, Germany, Canada, Switzerland, Austria, Denmark, Hungary, Netherlands, Poland, Israel, United Kingdom, Finland, Sweden, Norway, Czech Republic, Portugal, Slovenia
Radboud University Medical Center

Completed

The Effects of Interferon-gamma on Sepsis-induced Immunoparalysis

Sepsis | Septic Shock

Netherlands
Hospices Civils de Lyon

Recruiting

Human Recombinant Interferon Gamma in the Treatment of Ventilator-acquired Pneumonia in ICU Patients (IGNORANT)

Pneumonia, Ventilator-Associated

France
Bayer

Terminated

Rehabilitation Study in MS Patients

Multiple Sclerosis, Relapsing-Remitting

France
Pfenex, Inc

Completed

Comparison Study of PF530 and Betaferon in Healthy Subjects

Multiple Sclerosis

Australia
Bayer

Completed

Open, Multicentric, Prospective, Quality of Life Study in Multiple Sclerosis Patients

Multiple Sclerosis

France
Bayer

Completed

Injection Management With Betaferon: Influence on Adherence, Patients Satisfaction and Health Related Outcomes (BETAPATH)

Relapsing-Remitting Multiple Sclerosis

Germany
Bayer

Completed

China Betaferon Adherence, Coping and Nurse Support Study

Multiple Sclerosis, Chronic Progressive

China
Bayer

Completed

Prospective, Multicenter Non Interventional Study to Evaluate Adherence to Betaferon Over a 2 Years Period (SEPLUS)

Multiple Sclerosis

France
Rutgers, The State University of New Jersey
Bayer

Completed

Modulation of Plasmacytoid Dendritic Cell Function in Multiple Sclerosis

Multiple Sclerosis

United States
Bayer

Completed

Evaluation of Risk Factors for Early Termination of Injection Treatment With Betaferon in Patients Suffering From Multiple Sclerosis (BREAK)

Multiple Sclerosis

Poland
Bayer

Completed

Physical Activity and Fatigue in Early Multiple Sclerosis (MS) (BEGIN)

Multiple Sclerosis

Switzerland, France, Germany, Indonesia, Korea, Republic of, Spain, Sweden, Thailand, Taiwan, Australia, Austria, Colombia, Czech Republic, Italy, Jordan, Kazakhstan, Lebanon, Mexico, Slovenia, United Kingdom, Bahrain, Egypt, United... and more
Bayer

Completed

Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.

Multiple Sclerosis

Canada, United States
Bayer

Completed

Noninterventional Study Assessing Cognitive Function and Physical Activity in People With Multiple Sclerosis (CogniPlus)

Multiple Sclerosis

Turkey, Czechia, Hungary, Israel, Germany, France, Belgium, Greece, Netherlands, Egypt, Kazakhstan, Argentina, Portugal, Algeria, Saudi Arabia, Albania, Tunisia
Bayer

Completed

Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE) (INFLUENCE)

Multiple Sclerosis

Poland
Bayer

Completed

Open Label Study to Evaluate Effect, Safety and Tolerability of Betaferon Standard Dose of 250µg in Patients of Chinese Origin With Multiple Sclerosis

Multiple Sclerosis

China
Bayer

Withdrawn

Study to Compare Double-dose Betaferon to the Approved Dose, for Patients With Early Secondary Progressive Multiple Sclerosis (SPMS)

Multiple Sclerosis

Sweden, Denmark
Bayer

Completed

Extension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

United States
Bayer

Completed

Betaferon/ Betaseron (Interferon Beta-1b) in Patients With Chronic Viral Cardiomyopathy

Heart Diseases | Cardiomyopathies

Italy, Spain, Germany, Poland, United Kingdom, Sweden, France
Accelerated Community Oncology Research Network
InterMune

Completed

Study of Gamma Interfereon in Metastatic Colorectal Carcinoma (GFL)

Colorectal Cancer

United States
National Institute of Allergy and Infectious Diseases...

Completed

Adjuvant Cytokine Therapy to Treat Pulmonary Mycobacterium Avium Complex Infection

Mycobacterium Avium-Intracellulare Infection

United States
Bayer

Completed

US PROmyBETAapp2.0: A Study to Learn More About the Medication Usage and Patient Reported Outcomes Via the myBETAapp in Medical Care of Patients With Multiple Sclerosis Treated With BETASERON Using BETACONNECT Autoinjector

Multiple Sclerosis

United States
Bayer

Completed

Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis

United States, Canada
Bayer

Completed

BEYOND Pilot Study

Multiple Sclerosis | Relapsing-Remitting

United States
Kexing Biopharm Co., Ltd.
The Third Hospital of Changsha; Guoxin Pharmaceutical Technology (Beijing)... and other collaborators

Active, not recruiting

A Phase I Study of Human Interferon Alfa 1b Inhalation Solution in Healthy Participants

Healthy Participants

China
IRCCS Eugenio Medea

Completed

Open Trail of γIFN for Friedreich Ataxia

Friedreich Ataxia
Bayer

Completed

Impact of the BETACONNECT Auto-injector on BETASERON Therapy Adherence and Patient Satisfaction

Multiple Sclerosis, Relapsing-Remitting

United States
Bayer

Completed

BetaPlus Survey - Observational Study to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon® by Using Elements of the BetaPlus Program

Relapsing Remitting MS (RRMS) | Secondary Progressive MS (SPMS)

France, Germany, Korea, Republic of, Saudi Arabia, Spain, Taiwan, Czech Republic, Italy, Jordan, Lebanon, Turkey, Israel, Portugal, Netherlands, Iran, Islamic Republic of
Bayer

Completed

Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon (BETAPREDICT)

Multiple Sclerosis

Germany
Bayer

Completed

Study of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1b (ADHERENCE)

Multiple Sclerosis
Bayer

Completed

Betaferon® Regulatory Post-Marketing Surveillance

Multiple Sclerosis | Clinically Isolated System

Korea, Republic of
University of Colorado, Denver

Completed

Effect of IFN-γ on Innate Immune Cells

Chronic Granulomatous Disease

United States
Bayer

Completed

Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis (ROBUST)

Multiple Sclerosis, Relapsing-Remitting

United States

Search clinical trials for: interferon gamma 1b

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cambodia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations